Post-anti-cancer therapies, dying cancer cells release ATP and activate P2X7R in DCs, leading to IL-1β secretion via P2X7R-dependent NLRP-3 inflammasome assembly (306, 307), and this suggests the role of NLRP-3 inflammasome in the efficacy of anti-cancer therapies. Here, NLRP3 is linked to cancer.